导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.68% | 2018/4773 |
| 近一周 | -0.06% | 903/5465 |
| 近一月 | 4.86% | 90/5421 |
| 近一季 | 5.70% | 298/5231 |
| 近半年 | 4.95% | 832/4920 |
| 近一年 | 3.57% | 2044/4394 |
| 近两年 | 38.21% | 1975/2954 |
| 近三年 | 46.81% | 622/2253 |
| 成立以来 | 54.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.87% 2937/4961 |
-8.14% 3842/5312 |
- - |
- - |
| 2025 | 10.38% 2816/4813 |
2.45% 1365/3635 |
11.55% 165/4076 |
-8.51% 4046/4524 |
5.57% 425/4813 |
| 2024 | 38.72% 35/3463 |
9.80% 111/2808 |
6.85% 122/3014 |
12.41% 2352/3129 |
5.19% 628/3463 |
| 2023 | -2.26% 569/2656 |
-2.58% 2019/2280 |
2.21% 154/2385 |
4.76% 127/2515 |
-6.30% 1710/2655 |
| 2022 | -4.03% 76/2207 |
2.07% 82/1919 |
-1.32% 1705/2016 |
-7.79% 144/2113 |
3.34% 715/2208 |
| 2021 | - 732/1822 |
10.12% 48/1255 |
-2.53% 1211/1330 |
-6.54% 953/1466 |
-0.31% 1221/1822 |
| 2020 | 0.07% 939/1250 |
-14.03% 946/1028 |
1.88% 982/1067 |
4.61% 949/1164 |
9.22% 649/1184 |
| 2019 | 24.67% 613/1092 |
15.25% 688/754 |
2.35% 88/804 |
-0.52% 598/850 |
6.24% 639/918 |
| 2018 | -12.42% 83/834 |
- - |
- - |
- - |
-9.28% 140/691 |
| 2017 | 15.23% 248/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.98% 125/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华银行A VS. 长安沪深300非周期A(740101) |